Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210.

Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210. Abstract Text:

M J Straus,A Goldin,

Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210. Publishing Authors By Initials

MJ Straus,A Goldin,

For similar natural sciences: time: time factors research abstracts see: natural sciences: time: time factors research

PUBMED ID PMID:

MEDLINE DATE:

Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer chemotherapy reports. Part 1

VOLUME: 56

Page Numbers: 19-23

Journal Abbreviation:

ISSN: 0069-0112

DAY: 20

MONTH: Feb

YEAR: 1972

Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7607105

Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210. Keywords Mesh Terms:

KEYWORDS: Time Factors

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210. Information

Substance Name: Methotrexate

Registry Number: 59-05-2

Grant and Affiliation Information for Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer Chemother Rep

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Increased lifespan using the priming dose schedule design in carbazilquinone NSC-134679 treatment of mouse leukemia L1210 Related Publications

• 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962) and methotrexate (NSC-740) as combination therapy for advanced mouse leukemia L1210.
• Antileukemic action of a new sugar derivative dimethanesulfonate (NSC-122402) and related compounds in mice.
• Cancer chemotherapy; analysis of results of different screening techniques with nitrogen-mustard analogues.
• Cell-mediated response to a mouse leukemic subline antigenically altered following drug treatment in vivo.
• Chemotherapeutic response of epithelial tumors produced by primary implantation of a nonproducer line of murine sarcoma virus-transformed BALB 3T3 cells.
• Comparison of the antileukemic effect in mice of adriamycin (NSC-123127) with daunomycin (NSC-82151).
• Criteria for selection of new analogs of antitumor antibiotics.
• Duration effective levels of three antitumor drugs in mice with leukemia L1210 implanted intracerebrally and subcutaneously.
• Effect of 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962) and cyclophosphamide (NSC-26271) on nicotinamide adenine dinucleotide glycohydrolase in normal and leukemic mouse tissues.
• Effect of day of dosage omission on survival time in the regularly scheduled methotrexate (NSC-740) treatment of leukemia L1210.
• Effect of frozen storage on the response to therapy of drug-resistant transplantable mouse tumors.
• Effectiveness of daunomycin (NSC-82151) against experimental tumors.
• Effects of levamisole (NSC-177023) and tetramisole (NSC-102063) in experimental tumor systems.
• Evaluation of surgery and chemotherapy in the treatment of mouse mammary adenocarcinoma 755.
• Genomic abnormalities of the murine model of Fabry disease after disease-related perturbation, a systems biology approach.
• High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis.
• Increased immunogenicity of murine lymphatic tumors by pyrazole-4-carboxamide, 3(or 5)-amino (NSC-1402; PCA).
• Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210.
• Influence of mitotic cycle inhibitors on the antileukemic activity of cytosine arabinoside (NSC-63878) in mice bearing leukemia L1210.
• Influence of route of administration on antileukemic activity of cytosine arabinoside (NSC-63878) in advanced leukemia L1210 in mice.
• Influence of treatment schedules and route of administration on the chemotherapy of murine leukemia L1210 with 5(or 4)-[3,3-bis( 2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196).
• Paracolon endocarditis.
• Prevention of cyclophosphamide (NSC-26271) immunosuppression by bacillus Calmette-Guérin.
• Relationship between white blood cell count and diagnosis and therapeutic response in AKR mice with spontaneous leukemia (lymphoma).
• Semliki Forest virus vectors with mutations in the nonstructural protein 2 gene permit extended superinfection of neuronal and non-neuronal cells.
• Studies on therapeutic effectiveness of drugs with tumor weight and survival time indices of Walker 256 carcinosarcoma.
• The effect of folic-acid derivatives on sarcoma 180.
• The effect of restraint stress on the normal colon and on intestinal inflammation in a model of experimental colitis.
• Use of first generation transplants of a slow growing solid tumor for the evaluation of new cancer chemotherapeutic agents.
• [Electronic microscopy in the study of the structure of the brain.]